Doxycycline
- Generic Name
- Doxycycline
- Brand Names
- Acticlate, Adoxa, Apprilon, Atridox, Doryx, Doxy, Doxycin, Lymepak, Mondoxyne, Monodox, Morgidox, Okebo, Oracea, Periostat, Targadox, Vibramycin
- Drug Type
- Small Molecule
- Chemical Formula
- C22H24N2O8
- CAS Number
- 564-25-0
- Unique Ingredient Identifier
- 334895S862
- Background
Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
- Indication
Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria, including:
It is also used to treat infections caused by the following gram-negative microorganisms:
- Associated Conditions
- Acinetobacter Infections, Anthrax, Bacterial Infection caused by Enterobacter aerogenes, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydia Trachomatis Infection, Early Lyme Disease, Granuloma Inguinale, Infection Due to Escherichia Coli, Inhalational Anthrax, Klebsiella Infections, Lymphogranuloma Venereum, Malaria caused by Plasmodium falciparum, Nongonococcal urethritis, Plague caused by Yersinia pestis, Psittacosis, Rectal infection caused by Chlamydia Trachomatis, Relapsing fever caused by Borrelia recurrentis, Respiratory Tract Infection Bacterial, Rickettsial infectious disorders, Severe Acne, Sexually Transmitted Infections (STIs), Shigella Infection, Trachoma inclusion conjunctivitis, Tularemia, Vibrio Cholerae Infection, Acute Intestinal amebiasis, Susceptible Bacterial Infections, Uncomplicated endocervical infection, Uncomplicated urethral infection
ORCA - Oracea® for Rosacea: A Community-based Assessment
- Conditions
- Rosacea
- Interventions
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 1421
- Registration Number
- NCT00892281
- Locations
- 🇺🇸
REGISTRAT® - MAP1, Inc. (CRO), Lexington, Kentucky, United States
Microorganism in Overactive Bladder Patients
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2009-07-07
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 84
- Registration Number
- NCT00883818
- Locations
- 🇰🇷
Inha University College of Medicine, Inchon, Korea, Republic of
🇰🇷Asan Medical Center, Ulsan College of Medicine, Seoul, Korea, Republic of
🇰🇷Kangnam St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of
Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary DiseaseInflammationPulmonary Emphysema
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2009-03-06
- Lead Sponsor
- Medical Center Alkmaar
- Target Recruit Count
- 30
- Registration Number
- NCT00857038
- Locations
- 🇳🇱
Medical Center Alkmaar, Alkmaar, Noord-Holland, Netherlands
Efficacy of Topical Azelaic Acid 15% Gel Plus Anti-inflammatory Dose Doxycycline or Metronidazole Gel 1% Plus Anti-inflammatory Dose Doxycycline in Moderate Papulopustular Rosacea
- Conditions
- Papulopustular Rosacea
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- LEO Pharma
- Target Recruit Count
- 207
- Registration Number
- NCT00855595
Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 30
- Registration Number
- NCT00829790
- Locations
- 🇺🇸
CEDRA Clinical Research, San Antonio, Texas, United States
Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions
- First Posted Date
- 2009-01-27
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 30
- Registration Number
- NCT00829764
- Locations
- 🇺🇸
CEDRA Clinical Research, San Antonio, Texas, United States
Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash
- Conditions
- Non Small Cell Lung Cancer
- First Posted Date
- 2008-12-08
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00803842
Lipids of the Human Tear Film and Their Effect on Tear Stability
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2017-12-22
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 31
- Registration Number
- NCT00803452
- Locations
- 🇺🇸
Kentucky Lions Eye Center, Louisville, Kentucky, United States
Influence of MMP on Brain AVM Hemorrhage
- Conditions
- Arteriovenous MalformationsCavernous AngiomasBrain Aneurysms
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 33
- Registration Number
- NCT00783523
- Locations
- 🇺🇸
University of California, San Francisco, California, United States
Bioequivalence Study of Doxycycline Monohydrate 100mg Tablets Under Fasting Conditions
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2008-10-20
- Lead Sponsor
- Ranbaxy Laboratories Limited
- Target Recruit Count
- 32
- Registration Number
- NCT00775177
- Locations
- 🇺🇸
aaiPharma, Inc, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.